Stable transfectants of human MCF-7 breast cancer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolates

K. N. Chung, Y. Saikawa, T. H. Paik, K. H. Dixon, T. Mulligan, K. H. Cowan, P. C. Elwood

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

A major problem in cancer therapy is tumor drug resistance such as is found with antifolates (e.g., methotrexate [MTX]). We are specifically interested in the role of the human folate receptor (hFR) in MTX resistance. To investigate whether transfection of hFR results in increased MTX uptake and increased drug sensitivity, human mammary carcinoma (MCF-7) cells and Chinese hamster ovary cells (CHO) (cells which do not express detectable levels of hFR) were transfected with hFR cDNA. Stable human mammary carcinoma and Chinese hamster ovary transfectants expressing high levels of hFR were selected for further analysis. Transfected cells which express increased levels of hFR grow more rapidly than mock transfected or wild type cells in media containing physiologic concentrations of folates. The hFR expressed by these cells is sorted to the plasma membrane and is functional as determined by cell surface binding of a radiolabeled folic acid derivative and by internalization of [3H]methotrexate. The stable transfectants that express increased levels of hFR are also more sensitive to MTX in physiologic concentrations of folates. We conclude that increased expression of hFR by human mammary carcinoma and Chinese hamster ovary cells cultured under these conditions results in an enhanced growth rate, increased folic acid binding, and increased MTX uptake and cytotoxicity.

Original languageEnglish (US)
Pages (from-to)1289-1294
Number of pages6
JournalJournal of Clinical Investigation
Volume91
Issue number4
DOIs
StatePublished - Jan 1 1993

Fingerprint

Folic Acid Antagonists
Folic Acid
Breast Neoplasms
Methotrexate
Cricetulus
Ovary
MCF-7 Cells
Drug Resistance
Transfection

Keywords

  • cell growth
  • drug resistance
  • folate binding proteins
  • folic acid
  • methotrexate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Stable transfectants of human MCF-7 breast cancer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolates. / Chung, K. N.; Saikawa, Y.; Paik, T. H.; Dixon, K. H.; Mulligan, T.; Cowan, K. H.; Elwood, P. C.

In: Journal of Clinical Investigation, Vol. 91, No. 4, 01.01.1993, p. 1289-1294.

Research output: Contribution to journalArticle

@article{df0018c8d22f47418377054e876c7048,
title = "Stable transfectants of human MCF-7 breast cancer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolates",
abstract = "A major problem in cancer therapy is tumor drug resistance such as is found with antifolates (e.g., methotrexate [MTX]). We are specifically interested in the role of the human folate receptor (hFR) in MTX resistance. To investigate whether transfection of hFR results in increased MTX uptake and increased drug sensitivity, human mammary carcinoma (MCF-7) cells and Chinese hamster ovary cells (CHO) (cells which do not express detectable levels of hFR) were transfected with hFR cDNA. Stable human mammary carcinoma and Chinese hamster ovary transfectants expressing high levels of hFR were selected for further analysis. Transfected cells which express increased levels of hFR grow more rapidly than mock transfected or wild type cells in media containing physiologic concentrations of folates. The hFR expressed by these cells is sorted to the plasma membrane and is functional as determined by cell surface binding of a radiolabeled folic acid derivative and by internalization of [3H]methotrexate. The stable transfectants that express increased levels of hFR are also more sensitive to MTX in physiologic concentrations of folates. We conclude that increased expression of hFR by human mammary carcinoma and Chinese hamster ovary cells cultured under these conditions results in an enhanced growth rate, increased folic acid binding, and increased MTX uptake and cytotoxicity.",
keywords = "cell growth, drug resistance, folate binding proteins, folic acid, methotrexate",
author = "Chung, {K. N.} and Y. Saikawa and Paik, {T. H.} and Dixon, {K. H.} and T. Mulligan and Cowan, {K. H.} and Elwood, {P. C.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1172/JCI116327",
language = "English (US)",
volume = "91",
pages = "1289--1294",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "4",

}

TY - JOUR

T1 - Stable transfectants of human MCF-7 breast cancer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolates

AU - Chung, K. N.

AU - Saikawa, Y.

AU - Paik, T. H.

AU - Dixon, K. H.

AU - Mulligan, T.

AU - Cowan, K. H.

AU - Elwood, P. C.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - A major problem in cancer therapy is tumor drug resistance such as is found with antifolates (e.g., methotrexate [MTX]). We are specifically interested in the role of the human folate receptor (hFR) in MTX resistance. To investigate whether transfection of hFR results in increased MTX uptake and increased drug sensitivity, human mammary carcinoma (MCF-7) cells and Chinese hamster ovary cells (CHO) (cells which do not express detectable levels of hFR) were transfected with hFR cDNA. Stable human mammary carcinoma and Chinese hamster ovary transfectants expressing high levels of hFR were selected for further analysis. Transfected cells which express increased levels of hFR grow more rapidly than mock transfected or wild type cells in media containing physiologic concentrations of folates. The hFR expressed by these cells is sorted to the plasma membrane and is functional as determined by cell surface binding of a radiolabeled folic acid derivative and by internalization of [3H]methotrexate. The stable transfectants that express increased levels of hFR are also more sensitive to MTX in physiologic concentrations of folates. We conclude that increased expression of hFR by human mammary carcinoma and Chinese hamster ovary cells cultured under these conditions results in an enhanced growth rate, increased folic acid binding, and increased MTX uptake and cytotoxicity.

AB - A major problem in cancer therapy is tumor drug resistance such as is found with antifolates (e.g., methotrexate [MTX]). We are specifically interested in the role of the human folate receptor (hFR) in MTX resistance. To investigate whether transfection of hFR results in increased MTX uptake and increased drug sensitivity, human mammary carcinoma (MCF-7) cells and Chinese hamster ovary cells (CHO) (cells which do not express detectable levels of hFR) were transfected with hFR cDNA. Stable human mammary carcinoma and Chinese hamster ovary transfectants expressing high levels of hFR were selected for further analysis. Transfected cells which express increased levels of hFR grow more rapidly than mock transfected or wild type cells in media containing physiologic concentrations of folates. The hFR expressed by these cells is sorted to the plasma membrane and is functional as determined by cell surface binding of a radiolabeled folic acid derivative and by internalization of [3H]methotrexate. The stable transfectants that express increased levels of hFR are also more sensitive to MTX in physiologic concentrations of folates. We conclude that increased expression of hFR by human mammary carcinoma and Chinese hamster ovary cells cultured under these conditions results in an enhanced growth rate, increased folic acid binding, and increased MTX uptake and cytotoxicity.

KW - cell growth

KW - drug resistance

KW - folate binding proteins

KW - folic acid

KW - methotrexate

UR - http://www.scopus.com/inward/record.url?scp=0027230979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027230979&partnerID=8YFLogxK

U2 - 10.1172/JCI116327

DO - 10.1172/JCI116327

M3 - Article

C2 - 7682567

AN - SCOPUS:0027230979

VL - 91

SP - 1289

EP - 1294

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 4

ER -